Pola-ZR2P in Previously Untreated DLBCL

Conditions

• Diffuse Large B-cell Lymphoma

Eligibility Criteria

Sex

ALL

Age

14 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy — DRUG
  Patients were treated by Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Rituximab(375mg/m2 iv qd d1), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy

Study Details

The goal of this phase 2 trial is to test the safety and efficacy of Pola-ZR2P as induction therapy in patients with DLBCL.

Key Dates

Start date

Sep 24, 2024

Status verified

Aug 2025

Primary completion

Dec 31, 2029

Completion

Dec 31, 2030

Study Design

Enrollment

80 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Pola-ZR2P
  Patients were treated by Pola-ZR2P as Induction Therapy

Primary Outcome Measure

Progression Free Survival (PFS) [ Time Frame: 2 years ]

Central Contacts

• Liren Qian, PhD
  +861066947194
  [email protected]
• Liren Qian, PhD

Related Studies

• A Long-term Extension Study of PCI-32765 (Ibrutinib)
  PHASE3 · Recruiting · Janssen Research & Development, LLC · Duarte, California
• Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
  PHASE2 · Recruiting · New York Medical College · Valhalla, New York
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
  PHASE1/PHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
  Recruiting · Emory University · Atlanta, Georgia